Background:The objective of this work is to assess European cross-border multidisciplinary sarcoma tumor boards with regard to participation, adherence to treatment recommendations, and access to clinical trials and/or innovative therapeutic strategies. Methods:The European Reference Network for sarcomas (EURACAN G1 domain) aims to improve the diagnosis, the management, and the treatment of patients with these rare cancers.Cross-border multidisciplinary tumor boards were initiated to facilitate intercollegiate clinical discussions across Europe and increase patients' access to specialist treatment recommendations and clinical trials.All G1 physicians were invited to participate in bimonthly multidisciplinary virtual meetings.Patient data were collected using a standardized form and case summaries were distributed before each meeting.After each tumor board, a meeting summary with treatment recommendations was sent to all participants including to the project manager at the EURACAN coordinating center.Anonymized clinical data and treatment recommendations were registered in a prospective database.For this report, clinical data were collected between September 2023 and November 2025.Results: During the 2-year period, 12 multidisciplinary tumor boards were held with participants from 14 countries and 31 centers.Twenty-two individual patients were discussed.Follow-up data were retrieved from 21 patients.Overall, there were 15 different histotypes including 4 bone sarcomas (2 Ewing sarcomas and 2 osteosarcomas), the other being soft tissue mesenchymal tumors.Adherence to treatment recommendations was 97 %.The multidisciplinary tumor board recommendations resulted in four patients getting access to off-label treatment and one patient being enrolled in a clinical trial in another European country, while two patients were recommended for surveillance only. Conclusions:The EURACAN sarcoma tumor boards facilitate networking and close collaboration among physicians from Europe.For patients with rare cancers such as sarcomas, this might translate into benefits such as improved surveillance strategies, access to off-label treatments, and it could also provides greater opportunities to participate in clinical trials.
E.H. Hasanin (Sun,) studied this question.